Foghorn Therapeutics pauses enrollment in cancer study

Foghorn Therapeutics

24/04/2023 12:11

April 24 (Reuters) - Foghorn Therapeutics Inc  FHTX.O 
said on Monday it has paused enrollment in an early-stage study
of the company's experimental cancer drug due to safety
concerns.
    

 (Reporting by Khushi Mandowara in Bengaluru; Editing by Devika
Syamnath)
 ((Khushi.Mandowara@thomsonreuters.com;))